Evidence map›Paper›PMID 42161402›Full record

ArticleJournal for immunotherapy of cancer2026

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.

Yawei Ding, Kaifeng Jin, Xiaohe Su, Lingkai Zhang, Zhaopei Liu, Jiaxing Sun, Yuzhen Wu, Jinming Shi, Han Zeng, Hailong Liu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yawei DingDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kaifeng JinNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9867-6516
Xiaohe SuNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Lingkai ZhangNational Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei LiuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-5288-5037
Jiaxing SunDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yuzhen WuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jinming ShiDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Han ZengDepartment of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID http://orcid.org/0000-0001-6486-2038
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuanchang@fudan.edu.cn zwwang12@fudan.edu.cn.ORCID http://orcid.org/0000-0002-8833-3541
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuanchang@fudan.edu.cn zwwang12@fudan.edu.cn.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn weijuanzhang@fudan.edu.cn yuanchang@fudan.edu.cn zwwang12@fudan.edu.cn.ORCID http://orcid.org/0000-0003-3494-3114
Jiejie XuORCID http://orcid.org/0000-0001-7431-9063
Shanghai Urothelial Carcinoma Research Group (SUCRG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC,

methodsThis study integrated single-cell RNA sequencing, immunohistochemistry, and flow cytometry to delineate TAM phenotypes and map distinct immune landscapes stratified by p53 status. Clinical relevance was assessed in a multicohort dataset of 962 patients with UC with comprehensive clinicopathological annotations.

resultsSingle-cell profiling revealed distinct TAM subsets closely linked to p53 status. Interferon-primed TAMs, marked by

conclusionsIn UC, aberrant p53 status correlates with a remodeled TIME, characterized by metabolically reprogrammed, immunosuppressive TAMs. These TAMs co-evolve with suppressive CD4

Indexed as

MacrophagesTumor-Associated MacrophagesTumor Suppressor Protein p53Urinary Bladder NeoplasmsFemaleHumansMaleMutationTumor MicroenvironmentTP53 protein, humanTumor Suppressor Protein p53Bladder CancerChemotherapyImmune Checkpoint InhibitorMacrophageTumor microenvironment - TME

Identifiers

PMID42161402
PMCPMC13202007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.